Research map: Advancements in Immunotherapy for Lung Cancer: A Meta‐Analysis of Clinical Trial Outcomes

Back to the article

Papers in this map

  1. Bias in meta-analysis detected by a simple, graphical test · Matthias Egger · 1997 · 57818 citations · Cited by this paper
  2. Pulmonary Surfactant Treatment for Preterm Infants With Respiratory Distress Syndrome: A Nationwide Survey · 2026 · Related
  3. RoB 2: a revised tool for assessing risk of bias in randomised trials · Jonathan A C Sterne · 2019 · 33351 citations · Cited by this paper
  4. Pulmonary Sarcoidosis in Qatar: Clinical Features, Diagnostic Profile and Treatment Patterns in a Multi‐Ethnic Population · 2026 · Related
  5. Rayyan—a web and mobile app for systematic reviews · Mourad Ouzzani · 2016 · 26524 citations · Cited by this paper
  6. Associations of Serum CIRP and CXCL5 With Prognosis and Neutrophil Extracellular Traps in Pediatric Mycoplasma pneumoniae Pneumonia · 2026 · Related
  7. Cochrane Handbook for Systematic Reviews of Interventions · Farhad Shokraneh · 2019 · 14968 citations · Cited by this paper
  8. Stage III Lymph Node–Positive Non‐Small‐Cell Lung Cancer Patients With or Without Lymph Node Irradiation by Stereotactic Body Radiation Therapy: Propensity Score–Matched Analysis · 2025 · Related
  9. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews · Matthew James Page · 2021 · 11815 citations · Cited by this paper
  10. Venous Thromboembolism in Severe Community‐Acquired Pneumonia at High‐Altitude Areas: Prevalence, Risk and Outcome · 2026 · Related
  11. How to perform a meta-analysis with R: a practical tutorial · Sara Balduzzi · 2019 · 6001 citations · Cited by this paper
  12. Correction to “Clinical Features and Predictive Risk Factors for Prognosis in Invasive Pulmonary Aspergillosis and Pulmonary Mucormycosis” · 2026 · Related
  13. Risk‐of‐bias VISualization (robvis): An R package and Shiny web app for visualizing risk‐of‐bias assessments · Luke Aidan McGuinness · 2020 · 5531 citations · Cited by this paper
  14. Chinese Expert Consensus on the Testing Process, Quality Control and Clinical Application of Fractional Exhaled Nitric Oxide (2025) · 2026 · Related
  15. Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy · Nasser H. Hanna · 2004 · 2445 citations · Cited by this paper
  16. Issue Information · 2025 · Related
  17. Non-small cell lung cancer: current treatment and future advances · Cecilia Zappa · 2016 · 2044 citations · Cited by this paper
  18. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50% · Martin Reck · 2021 · 1185 citations · Cited by this paper
  19. Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study · Marina Chiara Garassino · 2023 · 725 citations · Cited by this paper
  20. Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study · Silvia Novello · 2023 · 563 citations · Cited by this paper
  21. Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial · Makoto Nishio · 2020 · 473 citations · Cited by this paper
  22. Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189 · Delvys Rodríguez‐Abreu · 2021 · 429 citations · Cited by this paper
  23. Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer · Karthik S. Suresh · 2018 · 397 citations · Cited by this paper
  24. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study · Gilberto de Castro · 2022 · 345 citations · Cited by this paper
  25. Reviewing retrieved references for inclusion in systematic reviews using EndNote · Wichor Matthijs Bramer · 2017 · 272 citations · Cited by this paper
  26. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis · Urania G. Dafni · 2019 · 229 citations · Cited by this paper
  27. Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1–Selected NSCLC · Jacek Jassem · 2021 · 213 citations · Cited by this paper
  28. Molecular heterogeneity in lung cancer: from mechanisms of origin to clinical implications · Federica Zito Marino · 2019 · 208 citations · Cited by this paper
  29. Immune checkpoint inhibitors: The linchpins of modern immunotherapy · Breelyn Ann Wilky · 2019 · 207 citations · Cited by this paper
  30. What's New in SCLC? A Review · Bryan T. Oronsky · 2017 · 198 citations · Cited by this paper
  31. Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC · Mark Magdi Awad · 2020 · 187 citations · Cited by this paper
  32. Current Landscape of Therapeutic Resistance in Lung Cancer and Promising Strategies to Overcome Resistance · Adnin Ashrafi · 2022 · 182 citations · Cited by this paper
  33. Real world data in the era of Immune Checkpoint Inhibitors (ICIs): Increasing evidence and future applications in lung cancer · Giulia Pasello · 2020 · 142 citations · Cited by this paper
  34. Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer · Triparna Sen · 2024 · 132 citations · Cited by this paper
  35. Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges · Etienne Giroux Leprieur · 2017 · 113 citations · Cited by this paper
  36. Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD‐L1‐positive locally advanced or metastatic non–small‐cell lung cancer: KEYNOTE‐042 China Study · Yi-Long Lung Cancer Wu · 2020 · 104 citations · Cited by this paper
  37. Immune checkpoint inhibitor combinations—current and emerging strategies · Robert John Walsh · 2023 · 92 citations · Cited by this paper
  38. Classification of Tumor Immune Microenvironment According to Programmed Death-Ligand 1 Expression and Immune Infiltration Predicts Response to Immunotherapy Plus Chemotherapy in Advanced Patients With NSCLC · Dongchen Sun · 2023 · 91 citations · Cited by this paper
  39. Novel chemotherapy regimens for advanced lung cancer: have we reached a plateau? · Panagiotis Baxevanos · 2018 · 84 citations · Cited by this paper

Source: OpenAlex (CC0)